211 related articles for article (PubMed ID: 18191334)
1. Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with definitive chemoradiation therapy.
Wei X; Liu HH; Tucker SL; Wang S; Mohan R; Cox JD; Komaki R; Liao Z
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(3):707-14. PubMed ID: 18191334
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for pericardial effusion in patients with stage I esophageal cancer treated with chemoradiotherapy.
Tamari K; Isohashi F; Akino Y; Suzuki O; Seo Y; Yoshioka Y; Hayashi Y; Nishida T; Takehara T; Mori M; Doki Y; Ogawa K
Anticancer Res; 2014 Dec; 34(12):7389-93. PubMed ID: 25503178
[TBL] [Abstract][Full Text] [Related]
3. Dose-volumetric parameters of acute esophageal toxicity in patients with lung cancer treated with three-dimensional conformal radiotherapy.
Kim TH; Cho KH; Pyo HR; Lee JS; Han JY; Zo JI; Lee JM; Hong EK; Choi IJ; Park SY; Shin KH; Kim DY; Kim JY
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):995-1002. PubMed ID: 15990000
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for acute esophagitis in non-small-cell lung cancer patients treated with concurrent chemotherapy and three-dimensional conformal radiotherapy.
Wei X; Liu HH; Tucker SL; Liao Z; Hu C; Mohan R; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):100-7. PubMed ID: 16839700
[TBL] [Abstract][Full Text] [Related]
5. Analysis of clinical and dosimetric factors associated with change in renal function in patients with gastrointestinal malignancies after chemoradiation to the abdomen.
May KS; Khushalani NI; Chandrasekhar R; Wilding GE; Iyer RV; Ma WW; Flaherty L; Russo RC; Fakih M; Kuvshinoff BW; Gibbs JF; Javle MM; Yang GY
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(4):1193-8. PubMed ID: 19540051
[TBL] [Abstract][Full Text] [Related]
6. Symptomatic pericardial effusion after chemoradiation therapy in esophageal cancer patients.
Fukada J; Shigematsu N; Takeuchi H; Ohashi T; Saikawa Y; Takaishi H; Hanada T; Shiraishi Y; Kitagawa Y; Fukuda K
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):487-93. PubMed ID: 23968770
[TBL] [Abstract][Full Text] [Related]
7. Dose-volume modeling of the risk of postoperative pulmonary complications among esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery.
Tucker SL; Liu HH; Wang S; Wei X; Liao Z; Komaki R; Cox JD; Mohan R
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):754-61. PubMed ID: 16965865
[TBL] [Abstract][Full Text] [Related]
8. Predictors of acute esophagitis in lung cancer patients treated with concurrent three-dimensional conformal radiotherapy and chemotherapy.
Rodríguez N; Algara M; Foro P; Lacruz M; Reig A; Membrive I; Lozano J; López JL; Quera J; Fernández-Velilla E; Sanz X
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):810-7. PubMed ID: 18755556
[TBL] [Abstract][Full Text] [Related]
9. Predictive factors for pericardial effusion identified by heart dose-volume histogram analysis in oesophageal cancer patients treated with chemoradiotherapy.
Hayashi K; Fujiwara Y; Nomura M; Kamata M; Kojima H; Kohzai M; Sumita K; Tanigawa N
Br J Radiol; 2015 Feb; 88(1046):20140168. PubMed ID: 25429644
[TBL] [Abstract][Full Text] [Related]
10. Dosimetric analysis of the patterns of local failure observed in patients with locally advanced non-small cell lung cancer treated with neoadjuvant chemotherapy and concurrent conformal (3D-CRT) chemoradiation.
Moreno-Jiménez M; Aristu J; López-Picazo JM; Ramos LI; Gúrpide A; Gómez-Iturriaga A; Valero J; Martínez-Monge R
Radiother Oncol; 2008 Sep; 88(3):342-50. PubMed ID: 18558448
[TBL] [Abstract][Full Text] [Related]
11. Doses of radiation to the pericardium, instead of heart, are significant for survival in patients with non-small cell lung cancer.
Xue J; Han C; Jackson A; Hu C; Yao H; Wang W; Hayman J; Chen W; Jin J; Kalemkerian GP; Matuzsak M; Jolly S; Kong FS
Radiother Oncol; 2019 Apr; 133():213-219. PubMed ID: 30416046
[TBL] [Abstract][Full Text] [Related]
12. Radiation pneumonitis following concurrent accelerated hyperfractionated radiotherapy and chemotherapy for limited-stage small-cell lung cancer: Dose-volume histogram analysis and comparison with conventional chemoradiation.
Tsujino K; Hirota S; Kotani Y; Kado T; Yoden E; Fujii O; Soejima T; Adachi S; Takada Y
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1100-5. PubMed ID: 16373082
[TBL] [Abstract][Full Text] [Related]
13. Dosimetric predictors of radiation-induced pericardial effusion in esophageal cancer.
Ogino I; Watanabe S; Sakamaki K; Ogino Y; Kunisaki C; Kimura K
Strahlenther Onkol; 2017 Jul; 193(7):552-560. PubMed ID: 28424841
[TBL] [Abstract][Full Text] [Related]
14. Dose-volume histogram parameters and clinical factors associated with pleural effusion after chemoradiotherapy in esophageal cancer patients.
Shirai K; Tamaki Y; Kitamoto Y; Murata K; Satoh Y; Higuchi K; Nonaka T; Ishikawa H; Katoh H; Takahashi T; Nakano T
Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):1002-7. PubMed ID: 20542385
[TBL] [Abstract][Full Text] [Related]
15. Analysis of dose-volume histogram parameters for radiation pneumonitis after definitive concurrent chemoradiotherapy for esophageal cancer.
Asakura H; Hashimoto T; Zenda S; Harada H; Hirakawa K; Mizumoto M; Furutani K; Hironaka S; Fuji H; Murayama S; Boku N; Nishimura T
Radiother Oncol; 2010 May; 95(2):240-4. PubMed ID: 20223539
[TBL] [Abstract][Full Text] [Related]
16. Dosimetric predictors of laryngeal edema.
Sanguineti G; Adapala P; Endres EJ; Brack C; Fiorino C; Sormani MP; Parker B
Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):741-9. PubMed ID: 17398024
[TBL] [Abstract][Full Text] [Related]
17. Association of clinical and dosimetric factors with postoperative pulmonary complications in esophageal cancer patients receiving intensity-modulated radiation therapy and concurrent chemotherapy followed by thoracic esophagectomy.
Hsu FM; Lee YC; Lee JM; Hsu CH; Lin CC; Tsai YC; Wu JK; Cheng JC
Ann Surg Oncol; 2009 Jun; 16(6):1669-77. PubMed ID: 19267157
[TBL] [Abstract][Full Text] [Related]
18. Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery.
Wang SL; Liao Z; Vaporciyan AA; Tucker SL; Liu H; Wei X; Swisher S; Ajani JA; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):692-9. PubMed ID: 16242257
[TBL] [Abstract][Full Text] [Related]
19. Pericardial effusion after definitive concurrent chemotherapy and intensity modulated radiotherapy for esophageal cancer.
Pao TH; Chang WL; Chiang NJ; Lin CY; Lai WW; Tseng YL; Lin FC
Radiat Oncol; 2020 Feb; 15(1):48. PubMed ID: 32103779
[TBL] [Abstract][Full Text] [Related]
20. Late toxicity after definitive concurrent chemoradiotherapy for thoracic esophageal carcinoma.
Morota M; Gomi K; Kozuka T; Chin K; Matsuura M; Oguchi M; Ito H; Yamashita T
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):122-8. PubMed ID: 19327900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
